CS272759B2 - Method of lyophilized adsorbed multivalent vaccines preparation - Google Patents

Method of lyophilized adsorbed multivalent vaccines preparation Download PDF

Info

Publication number
CS272759B2
CS272759B2 CS122584A CS122584A CS272759B2 CS 272759 B2 CS272759 B2 CS 272759B2 CS 122584 A CS122584 A CS 122584A CS 122584 A CS122584 A CS 122584A CS 272759 B2 CS272759 B2 CS 272759B2
Authority
CS
Czechoslovakia
Prior art keywords
lyophilized
antigens
dose
concentrated
pertussis
Prior art date
Application number
CS122584A
Other languages
Czech (cs)
English (en)
Other versions
CS122584A2 (en
Inventor
Zoltan Dr Csizer
Karoly Dr Sikos
Laszlo Bacskai
Istvan Dr Joo
Eleonora Dr Niedermayer
Lajos Dr Rethy
Jozsef Dr Zsidai
Original Assignee
Human Oltoanyagtermelo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Oltoanyagtermelo filed Critical Human Oltoanyagtermelo
Publication of CS122584A2 publication Critical patent/CS122584A2/cs
Publication of CS272759B2 publication Critical patent/CS272759B2/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CS122584A 1983-02-22 1984-02-22 Method of lyophilized adsorbed multivalent vaccines preparation CS272759B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU83609A HU188847B (en) 1983-02-22 1983-02-22 Process for producing liophylized combined vaccines

Publications (2)

Publication Number Publication Date
CS122584A2 CS122584A2 (en) 1990-06-13
CS272759B2 true CS272759B2 (en) 1991-02-12

Family

ID=10950430

Family Applications (1)

Application Number Title Priority Date Filing Date
CS122584A CS272759B2 (en) 1983-02-22 1984-02-22 Method of lyophilized adsorbed multivalent vaccines preparation

Country Status (18)

Country Link
US (1) US4578270A (it)
JP (1) JPS59196821A (it)
BE (1) BE898955A (it)
CA (1) CA1234048A (it)
CH (1) CH663901A5 (it)
CS (1) CS272759B2 (it)
DD (1) DD216384A5 (it)
DE (1) DE3406419A1 (it)
DK (1) DK82784A (it)
ES (1) ES8506451A1 (it)
FR (1) FR2541116B1 (it)
GB (1) GB2135190B (it)
HU (1) HU188847B (it)
IT (1) IT1196032B (it)
NL (1) NL8400511A (it)
PL (1) PL246306A1 (it)
PT (1) PT78132B (it)
YU (1) YU33284A (it)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS62162963A (ja) * 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4762710A (en) * 1986-06-16 1988-08-09 The United States Of America As Represented By The Department Of Health And Human Services Novel method of preparing toxoid by oxidation and metal ions
US5139776A (en) * 1987-04-24 1992-08-18 The Research Foundation For Microbial Diseases Of Osaka University Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine
CA1337859C (en) * 1987-04-24 1996-01-02 Masashi Chazono Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine
US5290563A (en) * 1989-07-27 1994-03-01 Laboratoire Des Stallergenes Method for combining a mixture of heterogeneous substances with liposomes
MX170503B (es) * 1990-05-10 1993-08-26 Univ Mexico , "procedimiento para obtener un reactivo antigenico util para determinar indirectamente salmonella typhi.
GB9125695D0 (en) * 1991-12-03 1992-01-29 Mastavac Limited Medical preparations
KR100291357B1 (ko) * 1993-01-08 2001-09-17 터베이 피터. 백신제제
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
GB2342922B (en) * 1998-10-19 2002-12-24 Jeyes Group Plc Lavatory cleansing block
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
CA2382652A1 (en) * 1999-08-24 2001-03-01 Teva Pharmaceutical Industries, Ltd. A vaccine composition and method of using the same
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
IL153241A0 (en) * 2000-06-08 2003-07-06 Powderject Vaccines Inc Powder compositions
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
CA2548179A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
CN102203002A (zh) * 2007-09-21 2011-09-28 细胞免疫科学公司 纳米治疗性胶态金属组合物和方法
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
WO2009062151A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0916570D0 (en) * 2009-09-21 2009-10-28 Royal Holloway & Bedford New C Method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2085391A (en) * 1934-01-31 1937-06-29 Sharp & Dohme Inc Lyophilic biologically active substances and process of producing the same
US3097140A (en) * 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
GB895073A (en) * 1959-11-23 1962-05-02 Wellcome Found Immunising preparations containing clostridium perfringens toxins and toxoids
US3395219A (en) * 1964-12-11 1968-07-30 Merck & Co Inc Process for production of pertussis antigen
NL6600706A (it) * 1965-02-05 1966-08-08
GB1081796A (en) * 1965-08-13 1967-08-31 Wright Fleming Inst Of Microbi Improvements in or relating to oily adjuvants for water-in-oil emulsions of antigenic materials
US3405218A (en) * 1965-09-22 1968-10-08 Parke Davis & Co Extracting bordetella pertussis antigens with lithium bromide
GB1145320A (en) * 1966-05-20 1969-03-12 Ustav Ser A Ockovacich Latek O Process for the preparation of bacterial cultures for vaccines against pertussis and
GB1152607A (en) * 1967-03-08 1969-05-21 Pfizer Ltd Antigenic Compositions
GB1218277A (en) * 1968-08-20 1971-01-06 Miles Lab Dry water-dispersible aluminium hydroxide gels
US3599150A (en) * 1969-08-01 1971-08-10 Miles Lab Stabilized aluminum hydroxide suspensions
FR2181426B1 (it) * 1972-04-06 1974-12-20 Pasteur Institut
FR2227861B1 (it) * 1973-05-04 1976-07-02 Anvar
DE2355094C3 (de) * 1973-11-03 1979-05-23 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Tetanus-Impfstoffs
DE2461439C3 (de) * 1974-12-24 1980-03-20 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines schützenden Antigens von Bordetella Pertussis sowie jenes enthaltendes Mittel
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines

Also Published As

Publication number Publication date
HU188847B (en) 1986-05-28
GB2135190A (en) 1984-08-30
IT1196032B (it) 1988-11-10
BE898955A (fr) 1984-08-20
CA1234048A (en) 1988-03-15
FR2541116B1 (fr) 1988-07-15
US4578270A (en) 1986-03-25
NL8400511A (nl) 1984-09-17
CH663901A5 (de) 1988-01-29
ES529961A0 (es) 1985-07-16
DK82784D0 (da) 1984-02-21
FR2541116A1 (fr) 1984-08-24
GB2135190B (en) 1986-10-22
ES8506451A1 (es) 1985-07-16
DD216384A5 (de) 1984-12-12
PT78132A (en) 1984-03-01
YU33284A (en) 1987-10-31
DE3406419A1 (de) 1984-08-23
PL246306A1 (en) 1985-02-27
JPS59196821A (ja) 1984-11-08
IT8419729A0 (it) 1984-02-21
PT78132B (en) 1986-05-19
GB8403921D0 (en) 1984-03-21
CS122584A2 (en) 1990-06-13
DK82784A (da) 1984-08-23

Similar Documents

Publication Publication Date Title
CS272759B2 (en) Method of lyophilized adsorbed multivalent vaccines preparation
KR880001098B1 (ko) 헤모필루스 인플루엔재 b 다당류 엑소톡소이드 배합체 왁진의 제조방법
EP0130619B1 (en) Hepatitis b vaccine and method for its preparation
CA1272952A (en) Glycoproteinic conjugates having trivalent immunogenic activity
KR100404312B1 (ko) 폴리리보실리비톨포스페이트를함유한백신조성물과이들의제조방법
US3743720A (en) Dry water-dispersible aluminum hydroxide gels
Dupuy et al. Immunopathology of Mouse Hepatitis Virus Type 3 Infection: II. Effect of Immunosuppression in Resistant Mice
DE19511276C2 (de) Adjuvans auf der Basis kolloidaler Eisenverbindungen
WO2019003238A1 (en) NOVEL MULTIVALENT VACCINE COMPOSITION CONTAINING POLYSACCHARIDE - PROTEIN CONJUGATES AND FORMULATION THEREOF
DE3787887T2 (de) Verfahren zum Züchten von Bordetella-Pertussis, ein Pertussis-Toxoid und ein Pertussis-Impfstoff.
PL211005B1 (pl) Sposób wytwarzania szczepionki zespolonej
Jezek et al. A heat-stable hepatitis B vaccine formulation
KR100289224B1 (ko) 조합 소아과 백신 조성물
Lunde et al. Characteristics of the Toxoplasma hemagglutination test antigen
Rolfe et al. Antigens of Bacteriophage øX174
EP1416958B1 (fr) Composition vaccinale comprenant au moins deux valances, l'une adjuvantee, l'autre pas
Cooper et al. Algammulin (gamma inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice
EP0339531A1 (en) Physiological active liquid allergenic composition from biological raw materials
Hobson The strain-specific serological activity of a non-haemagglutinating fraction of influenza viruses
CA1209036A (en) Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
EP4327820A1 (en) Liquid sextuple vaccine composition
SE463958B (sv) Foerfarande foer framstaellning av lyofiliserade, adsorberade, polyvalenta vacciner
CN116077638B (zh) 一种复合佐剂
Srivastava et al. Immunization of mice with components of Pasteurella multocida
CA2525615C (en) Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine